Patient's age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin
dc.contributor.author | Elefsiniotis, I. S. | en |
dc.contributor.author | Pavlidis, C. | en |
dc.contributor.author | Ketikoglou, I. | en |
dc.contributor.author | Koutsounas, S. | en |
dc.contributor.author | Scarmeas, N. | en |
dc.contributor.author | Pantazis, K. D. | en |
dc.contributor.author | Moulakakis, A. | en |
dc.contributor.author | Tsianos, E. V. | en |
dc.date.accessioned | 2015-11-24T18:59:53Z | |
dc.date.available | 2015-11-24T18:59:53Z | |
dc.identifier.issn | 1879-0828 | - |
dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/19434 | |
dc.rights | Default Licence | - |
dc.subject | Adult | en |
dc.subject | Age Factors | en |
dc.subject | Aged | en |
dc.subject | Antiviral Agents/*administration & dosage | en |
dc.subject | Biopsy, Needle | en |
dc.subject | Female | en |
dc.subject | Forecasting | en |
dc.subject | Genotype | en |
dc.subject | Greece | en |
dc.subject | Hepatitis C, Chronic/*drug therapy | en |
dc.subject | Humans | en |
dc.subject | Interferon-alpha/*administration & dosage | en |
dc.subject | Liver/*pathology/virology | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Polyethylene Glycols/*administration & dosage | en |
dc.subject | Recombinant Proteins | en |
dc.subject | Retrospective Studies | en |
dc.subject | Ribavirin/*administration & dosage | en |
dc.subject | Treatment Outcome | en |
dc.subject | Viral Load | en |
dc.title | Patient's age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin | en |
heal.abstract | BACKGROUND: The aim of this study was to investigate the effect of patient's age on the impact of typically proposed predictors of sustained virological response (SVR) in treatment-naive, high-pretreatment viral load (>700.000 IU/ml), chronic hepatitis C (CHC) patients treated under real-life conditions in Greece. METHODS: We retrospectively analyzed 185 CHC patients (14.4% cirrhotics) who had been treated with weight-adjusted dosing (1.5 microg/kg per week) of pegylated interferon-a2b (PEG) plus genotype-based ribavirin (RIB) for 24 or 48 weeks of treatment, based on viral genotype. SVR was confirmed by undetectable serum HCV-RNA 6 months after the end of treatment. RESULTS: Overall, 68.5% of patients exhibited SVR and 31.5% were non-responders (non-SVRs). Among the non-SVRs, 71.4% were infected with HCV genotype-1. Importantly, 71.4% of genotype 4-infected treated patients exhibited SVR. In the multivariate analyses, only the early histological stage of liver disease (p=0.015) and the presence of genotype non-1 infection (p=0.003) were independent predictors of SVR. For patients younger than 35 years, none of the baseline parameters and neither viral genotype (p=0.284) nor the stage of liver disease (p=0.351) was an independent predictor of non-SVR, whereas for patients between 35 and 55, only the presence of genotype-1 infection independently predicted non-SVR (p=0.008). For older patients (>55 years), only the histological stage of liver disease (p=0.047) and not the viral genotype (p=0.275) independently predicted non-SVR. CONCLUSIONS: The impact of the typical predictors of SVR, such as viral genotype and liver histopathology, is modified according to patient's age in currently approved combination treatment. | en |
heal.access | campus | - |
heal.fullTextAvailability | TRUE | - |
heal.identifier.primary | 10.1016/j.ejim.2007.06.014 | - |
heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/18471675 | - |
heal.identifier.secondary | http://ac.els-cdn.com/S0953620507003536/1-s2.0-S0953620507003536-main.pdf?_tid=cdf2ffe3539831b8de5652fae8a8d0a5&acdnat=1333694941_c5bbe4009e00fe3f233c6e79d5ecceb5 | - |
heal.journalName | Eur J Intern Med | en |
heal.journalType | peer-reviewed | - |
heal.language | en | - |
heal.publicationDate | 2008 | - |
heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
heal.type | journalArticle | - |
heal.type.el | Άρθρο Περιοδικού | el |
heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: